Kadcyla (Trastuzumab Emtansine)

Trastuzumab emtansine combines a HER2‑targeting antibody with the cytotoxic agent DM1. The antibody binds to HER2 receptors on cancer cells, the complex is internalized, and DM1 is released inside the cell where it disrupts microtubule assembly, leading to cell‑cycle arrest and apoptosis.

The dosing regimen for Kadcyla is determined by the prescribing oncologist based on the patient’s clinical condition, body weight, and treatment protocol. Specific dose amounts and infusion schedules are individualized and should follow the prescriber’s instructions.

Kadcyla is not recommended for use during pregnancy or while breastfeeding because its safety has not been established and it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period defined by their physician.

To order Kadcyla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, cold‑chain shipping details and necessary import documentation.

The primary alternative is trastuzumab (Herceptin), a HER2‑targeted monoclonal antibody without a cytotoxic payload. Kadcyla delivers the additional DM1 toxin, offering a higher potency against HER2‑positive tumors but with a broader safety profile. Choice depends on disease stage, prior therapy, and patient tolerance.

Kadcyla must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, the solution is inspected for particulate matter and discoloration.

Kadcyla is given as an intravenous infusion. The prescribed dose is diluted in a compatible IV fluid and infused over a period typically ranging from 30 to 90 minutes, depending on the patient’s tolerance and the infusion protocol set by the treating physician.

Serious risks include cardiac dysfunction (reduced left‑ventricular ejection fraction or heart failure), interstitial lung disease or pneumonitis, and severe infusion‑related reactions such as anaphylaxis. Patients should be monitored closely for symptoms of these conditions throughout treatment.

Kadcyla should not be used in patients with known hypersensitivity to trastuzumab, emtansine, or any component of the formulation. It is also contraindicated in individuals with severe uncontrolled cardiac disease, active uncontrolled infections, or in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.